Prestige Biologics Co., Ltd.

A334970

KR7334970001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
4,235 ^KRW	+2.54%		+3.17%	-3.75%

2023	Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited	CI
2023	Prestige Biologics Co., Ltd. announced that it expects to receive KRW 45.5 billion in funding from Octava Fund Limited	CI

Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited

March 19, 2023

On March 20, 2023, Prestige Biologics Co., Ltd. closed the transaction.

Latest news about Prestige Biologics Co., Ltd.

Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited	23-03-19	CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 45.5 billion in funding from Octava Fund Limited	23-03-13	CI
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma Limited	22-09-04	CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited	22-08-25	CI
Prestige BioPharma and Dr. Reddy's Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	21-12-08	CI
Prestige Biologics Co., Ltd.(KOSDAQ:A334970) added to S&P Global BMI Index	21-09-20	CI
Prestige Biologics Co., Ltd. has completed an IPO in the amount of KRW 91.14 billion.	21-03-08	CI
Prestige Biologics Co., Ltd. has filed an IPO.	20-08-21	CI

Chart Prestige Biologics Co., Ltd.

Duration

Period

More charts

Prestige Biologics Co Ltd is a Korean-based company mainly engaged in the business of developing and manufacturing biopharmaceuticals. The Company mainly engages in the contract manufacturing service business that produces and supplies biopharmaceuticals; and contract development service business that provides development services including cell culture process and purification process.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
PRESTIGE BIOLOGICS CO., LTD.	-3.75%	192M
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B
INNOVENT BIOLOGICS, INC.	-6.32%	8.35B

Biopharmaceuticals